Mucositis in malignant hematology

References

• Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol.45(12), 1015–1020 (2009).
   PubMed Web of Science ®Google Scholar
• Niscola P, Romani C, Cupelli L et al. Mucositis in patients with hematologic malignancies: an overview. Haematologica92(2), 222–231 (2007).
   PubMed Web of Science ®Google Scholar
• Sonis ST. The pathobiology of mucositis. Nat. Rev.30, 277 (2004).
   Google Scholar
• Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother. Pharmacol.63(2), 239–251 (2009).
   PubMed Web of Science ®Google Scholar
• Kaplan JR, Wolf JS Jr. Efficacy and survival associated with cystoscopy and clot evacuation for radiation or cyclophosphamide induced hemorrhagic cystitis. J. Urol.181(2), 641–646 (2009).
   PubMedGoogle Scholar
• Matteucci P, Carlo-Stella C, Di Nicola M et al. Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside. Haematologica91(2), 255–257 (2006).
   PubMed Web of Science ®Google Scholar
• Niscola P, Romani C, Scaramucci L et al. Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies. Bone Marrow Transplant.41(9), 757–764 (2008).
   PubMed Web of Science ®Google Scholar
• Ramírez-Amador V, Anaya-Saavedra G, Crespo-Solís E, Camacho EI, González-Ramírez I, Ponce-de-León S. Prospective evaluation of oral mucositis in acute leukemia patients receiving chemotherapy. Support Care Cancer DOI: 10.1007/s00520-009-0708-1 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Sonis ST, Oster G, Fuchs H et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J. Clin. Oncol.19(8), 2201–2205 (2001).
   PubMed Web of Science ®Google Scholar
• Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Serum levels of NF-κB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol. Ther.7(7), 1139–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Logan RM, Gibson RJ, Sonis ST, Keefe DM. Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol.43(4), 395–401 (2007).
   PubMed Web of Science ®Google Scholar
• Hwang D, Popat R, Bragdon C, O’Donnell KE, Sonis ST. Effects of ceramide inhibition on experimental radiation-induced oral mucositis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.100(3), 321–329 (2005).
   PubMed Web of Science ®Google Scholar
• Al-Dasooqi N, Gibson RJ, Bowen JM, Keefe DM. Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer Chemother. Pharmacol.64(1), 1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Bowen JM, Gibson RJ, Cummins AG, Keefe DM. Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer14(7), 713–731 (2006).
   PubMed Web of Science ®Google Scholar
• Keefe DM. Intestinal mucositis: mechanisms and management. Curr. Opin. Oncol.19(4), 323–327 (2007).
   PubMed Web of Science ®Google Scholar
• Stringer AM, Gibson RJ, Bowen JM, Keefe DM. Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr. Drug Metab.10(1), 79–83 (2009).
   PubMed Web of Science ®Google Scholar
• Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol.9, 91–100 (2003).
   Google Scholar
• Sonis ST, Elting LS, Keefe D et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer100(9 Suppl.), 1995–2025 (2004).
   PubMed Web of Science ®Google Scholar
• Keefe D, Anthony L. Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care. Curr. Opin. Support Palliat. Care2(1), 19–21 (2008).
   PubMedGoogle Scholar
• Gerson SL, Bhalla KN, Grant S, Creger RJ, Bahlis NJ. Pharmacology and molecular mechanisms of antineoplastic agents for hematologic malignancies. In: Hematology, Basic Principles and Practice. (Fourth Edition) Hoffman R, Benz EJ Jr, Shattil SJ et al. (Eds). Elsevier, Churchill Livingstone, PA, USA 955–1017 (2005).
   Google Scholar
• Robien K, Schubert MM, Chay T et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation. Bone Marrow Transplant.37(8), 799–800 (2006).
   PubMed Web of Science ®Google Scholar
• Gemmati D, Ongaro A, Tognazzo S et al. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin’s lymphoma patients: association with toxicity and survival. Haematologica92(4), 478–485 (2007).
   PubMed Web of Science ®Google Scholar
• Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet. Genomics15, 801–815 (2005).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med.346(4), 235–242 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson PW, Radford JA, Cullen MH et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom Lymphoma group LY09 Trial (ISRCTN97144519). J. Clin. Oncol.23(36), 9208–9218 (2005).
   PubMed Web of Science ®Google Scholar
• Friedenberg WR, Miller HJ, Marx JJ Jr et al. The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy. Am. J. Clin. Oncol.18(2), 105–110 (1995).
   PubMed Web of Science ®Google Scholar
• Pea F, Russo D, Michieli M et al. M. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia. Clin Pharmacokinet.42(9), 851–862 (2003).
   PubMed Web of Science ®Google Scholar
• Ferrara F, Palmieri S, Pocali B et al.De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur. J. Haematol.68(4), 203–209 (2002).
   PubMed Web of Science ®Google Scholar
• Pastore D, Specchia G, Carluccio P et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann. Hematol.82(4), 231–235 (2003).
   PubMed Web of Science ®Google Scholar
• Girmenia C, Lo Coco F, Breccia M et al. Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. Leukemia17(5), 925–930 (2003).
   PubMed Web of Science ®Google Scholar
• Wang EH, Chen YA, Corringham S et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant.34(7), 581–587 (2004).
   PubMed Web of Science ®Google Scholar
• Blijlevens N, Schwenkglenks M, Bacon P et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy – European Blood and Marrow Transplantation Mucositis Advisory group. J. Clin. Oncol.26(9), 1519–1525 (2008).
   PubMed Web of Science ®Google Scholar
• Ozturk M, Komurcu S, Kilic S et al. Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. Support Care Cancer17(10), 1295–1299 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrara F, Palmieri S, De Simone M et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br. J. Haematol.128(2), 234–241 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrara F, Palmieri S, Pedata M et al. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan. Hematol. Oncol.27(1), 40–45 (2009).
   PubMed Web of Science ®Google Scholar
• Kröger N, Zabelina T, Krüger W et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant.27(4), 349–354 (2001).
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Attal M et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood99(3), 731–735 (2002).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Petrucci MT et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70:results of a randomized controlled trial. Blood104(10), 3052–3057 (2004).
   PubMed Web of Science ®Google Scholar
• Bolwell BJ, Kalaycio M, Sobecks R et al. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant.30(9), 587–591 (2002).
   PubMed Web of Science ®Google Scholar
• Wardley AM, Jayson GC, Swindell R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br. J. Haematol.110(2), 292–299 (2000).
   PubMed Web of Science ®Google Scholar
• Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J. Clin. Oncol.22, 1268–1275 (2004).
   PubMed Web of Science ®Google Scholar
• Cutler C, Li S, Kim HT et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol. Blood Marrow Transplant.11(5), 383–388 (2005).
   PubMed Web of Science ®Google Scholar
• Takahashi K, Soga Y, Murayama Y et al. Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: comparison with conventional regimen. Support Care Cancer DOI: 10.1007/s00520-009-0637-z (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Quinn B, Potting CM, Stone R et al. Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur. J. Cancer44(1), 61–72 (2008).
   PubMed Web of Science ®Google Scholar
• WCCNR. Assessing stomatitis: refinement of the Western Consortium for Cancer Nursing Research (WCCNR) stomatitis staging system. Can. Oncol. Nurs. J.8, 160–165 (1998).
   PubMedGoogle Scholar
• Cella D, Pulliam J, Fuchs H et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer98(2), 406–412 (2003).
   PubMed Web of Science ®Google Scholar
• Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer8(1), 33–39 (2000).
   PubMed Web of Science ®Google Scholar
• van der Velden WJ, Blijlevens NM, Feuth T, Donnelly JP. Febrile mucositis in haematopoietic SCT recipients. Bone Marrow Transplant.43(1), 55–60 (2009).
   PubMed Web of Science ®Google Scholar
• Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer72, 1612–1617 (1993).
   PubMed Web of Science ®Google Scholar
• Miaskowski C. Biology of mucosal pain. J. Natl Cancer Inst. Monographs29, 37–40 (2001).
   Google Scholar
• Triantafyllou K, Dervenoulas J, Tsirigotis P, Ladas SD. The nature of small intestinal mucositis: a video-capsule endoscopy study. Support Care Cancer16(10), 1173–1178 (2008).
   PubMed Web of Science ®Google Scholar
• Blijlevens NM, Donnelly JP, Yakar D, van Die CE, de Witte T. Determining mucosal barrier injury to the oesophagus using CT scan. Support Care Cancer15(9), 1105–1108 (2007).
   PubMed Web of Science ®Google Scholar
• Canaud G, Vasiliu V, Suarez F. Clinical challenges and images in GI. Esophageal mucosa expulsion after high-dose chemotherapy. Gastroenterology136(5), 1508, 1847 (2009).
   PubMed Web of Science ®Google Scholar
• Davila ML. Neutropenic enterocolitis. Curr. Opin. Gastroenterol.22(1), 44–47 (2006).
   PubMed Web of Science ®Google Scholar
• Siniscalchi A, Tendas A, Ales M et al. Bortezomib-related colon mucositis in a multiple myeloma patient. Support Care Cancer17(4), 325–327 (2009).
   PubMed Web of Science ®Google Scholar
• Rubenstein EB, Peterson DE, Schubert M et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer100(9 Suppl.), 2026–2046 (2004).
   PubMed Web of Science ®Google Scholar
• Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer109(5), 820–831 (2007).
   PubMed Web of Science ®Google Scholar
• Bensinger W, Schubert M, Ang KK et al. NCCN Task Force Report: prevention and management of mucositis in cancer care. J. Natl Compr. Canc. Netw.6(Suppl. 1), S1–21 (2008).
   PubMedGoogle Scholar
• Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol.27(1), 127–145 (2009).
   PubMed Web of Science ®Google Scholar
• Lövenich H, Schütt-Gerowitt H, Keulertz C et al. Failure of anti-infective mouth rinses and concomitant antibiotic prophylaxis to decrease oral mucosal colonization in autologous stem cell transplantation. Bone Marrow Transplant.35(10), 997–1001 (2005).
   PubMed Web of Science ®Google Scholar
• von Bültzingslöwen I, Brennan MT, Spijkervet FK et al. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer14(6), 519–527 (2006).
   PubMed Web of Science ®Google Scholar
• Potting CM, Uitterhoeve R, Op Reimer WS, Van Achterberg T. The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review. Eur. J. Cancer Care (Engl.)15(5), 431–439 (2006).
   PubMed Web of Science ®Google Scholar
• Vokurka S, Bystrická E, Koza V et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT – results of a randomized multicentre study. Support Care Cancer13(7), 554–558 (2005).
   PubMed Web of Science ®Google Scholar
• Lockhart PB, Brennan MT, Kent ML et al. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplant.35(7), 713–720 (2005).
   PubMed Web of Science ®Google Scholar
• Elad S, Ackerstein A, Bitan M et al. A prospective, double-blind Phase II study evaluating the safety and efficacy of a topical histamine gel for the prophylaxis of oral mucositis in patients post hematopoietic stem cell transplantation. Bone Marrow Transplant.37(8), 757–762 (2006).
   PubMed Web of Science ®Google Scholar
• Sironi M, Milanese C, Vecchi A et al. Benzydamine inhibits the release of tumor necrosis factor-α and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells. Int. J. Clin. Lab. Res.27(2), 118–122 (1997).
   PubMedGoogle Scholar
• Thieblemont C, Dumontet C, Saad H et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant.30(11), 769–775 (2002).
   PubMed Web of Science ®Google Scholar
• Crowther M, Avenell A, Culligan DJ. Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation. Bone Marrow Transplant.44(7), 413–425 (2009).
   PubMed Web of Science ®Google Scholar
• Lalla RV, Schubert MM, Bensadoun RJ, Keefe D. Anti-inflammatory agents in the management of alimentary mucositis. Support Care Cancer14, 558–565 (2006).
   PubMed Web of Science ®Google Scholar
• Migliorati CA, Oberle-Edwards L, Schubert M. The role of alternative and natural agents, cryotherapy, and/or laser for management of alimentary mucositis. Support Care Cancer14, 533–540 (2006).
   PubMed Web of Science ®Google Scholar
• Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 16, 351(25), 2590–2598 (2004).
   PubMed Web of Science ®Google Scholar
• Niscola P, Scaramucci L, Giovannini M et al. Palifermin in the management of mucositis in hematological malignancies: current evidences and future perspectives. Cardiovasc. Hematol. Agents Med. Chem.7(4), 305–312 (2009).
   PubMedGoogle Scholar
• Epstein JB, Schubert MM. Managing pain in mucositis. Semin. Oncol. Nurs.20, 30–37 (2004).
   PubMedGoogle Scholar
• Cerchietti LC, Navigante AH, Körte MW et al. Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain105(1–2), 265–273 (2003).
   PubMed Web of Science ®Google Scholar
• Epstein JB, Epstein JD, Epstein MS, Oien H, Truelove EL. Doxepin rinse for management of mucositis pain in patients with cancer: one week follow-up of topical therapy. Spec. Care Dentist.28(2), 73–77 (2008).
   PubMedGoogle Scholar
• Keefe DM. Mucositis guidelines: what have they achieved, and where to from here? Support Care Cancer14(6), 489–491 (2006).
   PubMed Web of Science ®Google Scholar
• Bowen JM, Keefe DM. New pathways for alimentary mucositis. J. Oncol. 907892 (2008).
   Google Scholar
• Keefe DM, Sonis ST, Bowen JM. Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg. Drugs.13(3), 511–522 (2008).
   PubMed Web of Science ®Google Scholar
• Evans WE, McLeod HL. Pharmacogenomics; drug disposition, drug targets, and side effects. N. Engl. J. Med.348, 538–549 (2003).
   PubMed Web of Science ®Google Scholar
• Chung HM, Lyckholm LJ, Smith TJ. Palliative care in BMT. Bone Marrow Transplant.43(4), 265–273 (2009).
   PubMed Web of Science ®Google Scholar